-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Capricor Therapeutics, Raises Price Target to $54

Benzinga·12/08/2025 13:52:38
語音播報
Oppenheimer analyst Leland Gershell maintains Capricor Therapeutics (NASDAQ:CAPR) with a Outperform and raises the price target from $22 to $54.